Oculis Holding AG - Ordinary shares (NQ:OCS)

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

October 20, 2026

Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

Performance

52-Week Range 76.5% below 52-week high

8.090

7.1152W Low 34.4852W High

1 Week

7.151W Low 8.021W High

Oculis Holding AG - Ordinary shares (OCS) traded between $7.11 and $34.48 over the past 52 weeks and last traded at $8.09, 76.5% below its 52-week high. Over the past week it ranged between $7.15 and $8.02.

Past 12 Months

+9.3%

-20.2%

-29.2%

-71.0%

-59.5%

-62.9%

1W +$0.69

1M -$2.05

3M -$3.34

6M -$19.76

YTD -$11.91

1Y -$13.73

OCS was -62.9% over the past year, -71.0% over six months, -59.5% year to date, +9.3% in the last week.

12 Months vs Market

OCS

-62.9%

DIA

+12.5%

SPY

+13.8%

QQQ

+15.2%

IWM

+12.0%

Over the past 12 months OCS returned -62.9% versus DIA (Dow) +12.5%, SPY (S&P 500) +13.8%, QQQ (Nasdaq 100) +15.2% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 1.61× 3-mo avg

Today 427,594 3-mo avg 266.1K

356.8K

324.7K

266.1K

486.8K

YTD

425.6K

362.8K

OCS most recently traded 427,594 shares against a 3-month average daily volume of 266.1K.

More News

October 19, 2026

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

October 07, 2026

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

October 01, 2026

Oculis (NASDAQ:OCS) Beats Q2 Estimates and Advances Late-Stage Neuro-Ophthalmology Pipeline ↗

August 06, 2026

Via Chartmill

Oculis Announces Resignation of Lionel Carnot from Board of Directors

September 30, 2026

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

August 24, 2026

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

August 10, 2026

Oculis Reports Q2 2026 Financial Results and Provides Company Update

August 06, 2026

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

August 03, 2026

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

July 02, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 23, 2026

OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

June 17, 2026

From Schall Law

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 16, 2026

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

June 11, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 09, 2026

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease

June 09, 2026

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

June 08, 2026

OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗

June 08, 2026

Via The Motley Fool

June 04, 2026

From The Schall Law Firm

Via Business Wire

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗

June 03, 2026

Via The Motley Fool

OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud

June 03, 2026

From Levi & Korsinsky, LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS

June 02, 2026